Author: YL
VDP-16: Korolchuk Laboratory - Autophagy Activator
VDP-16: Korolchuk Laboratory - Autophagy Activator
https://snapshot.box/#/s:vote.vitadao.eth/proposal/0xc6b8c449b4ba7ab145f77d871d14d80c77be5fbfac1489855a05de0e112b3ac0
Summary: The VDP-16 project from the Korolchuk Laboratory aims to discover new autophagy activators through screening a library of natural compounds to combat aging and related diseases.
Overview: The VDP-16 project proposed by the Korolchuk Laboratory aims to combat aging and related diseases by activating the autophagy pathway. Autophagy is a process by which cells clear damaged components, and its function diminishes with aging. The project simulates lysosomal dysfunction using Npc1 mutant cell models, which impedes the terminal stage of autophagy and affects cell survival. The Korolchuk Laboratory plans to screen a unique library of natural compounds and synthesize derivatives of these compounds to identify their biological targets. The project employs a high-throughput cell death-based screening system capable of rapidly identifying true autophagy activators. The project team consists of Viktor Korolchuk, Jóhannes Reynisson, and Konstantin Volcho, who have extensive experience in cell biology, drug discovery, and organic chemistry.
Extended Understanding:
YL Comment: Immune activation can be achieved through alternating hot and cold therapies in hot springs, commonly popular among athletes for post-training recovery. However, enhancing the autophagic function of damaged cells through external forces is challenging, and with aging, autophagic function gradually weakens. Autophagy activators have broad commercial prospects once transformed into anti-aging health products. All VITA token holders are potential consumers.
VDP-17: Collaboration with Crowd Funded Cures (Re-Development of Effective Generic Drugs)
VDP-17: Collaboration with Crowd Funded Cures
https://snapshot.box/#/s:vote.vitadao.eth/proposal/0x339640e0ae12bd2ff4980c69281dac5c7ecc084ba65ac148c37918effd01acdc
Summary: VitaDAO provides $40,000 in funding to support Crowd Funded Cures in a feasibility study.
Overview: The VDP-17 proposal aims to address the repositioning of pan-drugs and nutritional supplements, focusing on re-screening 20,000 FDA-approved generic drugs available in the market, some of which have expired patents or are no longer maintained.
Extended Understanding:
YL Comment: Reutilizing existing expired patent drugs can significantly reduce the cost and time of developing new drugs. The Crowd Funded Cures model allows these drugs to undergo clinical trials without the need for high patent protection, thus accelerating the market entry process.
VDP-18 Jonathan An - Reversing Periodontal Disease Using Aging Science
VDP-18: Jonathan An - Reversing Periodontal Disease Using Aging Science
https://snapshot.box/#/s:vote.vitadao.eth/proposal/0x8464713774628fa0af6262478f7c1ecccb0a3272cc72f6324183f598e9f29007
Summary: Funding of up to $300,000 is provided for Jonathan An's research project, aimed at exploring the possibility of reversing age-related periodontal disease using Geroscience methods.
Overview: The VDP-18 proposal aims to fund Dr. Jonathan An's research, which seeks to develop new treatments for age-related periodontal disease through small molecule inhibitors targeting the PI3K/NFkB/mTOR signaling pathway. This research is based on a paper published in eLife, which demonstrated positive effects of oral rapamycin treatment on age-related periodontal osteoporosis in mouse models. The research team plans to test five candidate drugs over an 8-week study and compare them with rapamycin. If systemic treatment proves effective, the research will further explore local delivery methods for these drugs. Additionally, the study will assess the impact of these drugs on neurodegeneration and cognitive function. The expected outcomes of the research will provide important preclinical intellectual property (IP) data for non-surgical treatment methods for periodontal disease and may lead to the establishment of new companies.
Extended Understanding:
YL Comment: The global trend of population aging is evident, with projections indicating that by 2050, the population aged 65 and older will reach 2 billion. This large elderly population has an increasing demand for health management, disease prevention, and treatment, with the output of results including clinical intellectual property (IP) data and potential drug delivery. Pfizer is the investor behind this, and there is no shortage of channels in drug production.
VDP-21 Discovering New Mitochondrial Autophagy Activators with Evandro Fang
VDP-21: Discovering New Mitochondrial Autophagy Activators with Evandro Fang
https://snapshot.box/#/s:vote.vitadao.eth/proposal/0xc46ee26737580c579c383c61f03ac7291e4a5cc243a6b334e1b8b41ab036afe3e
Summary: A research project led by Evandro Fang aims to discover new apoptosis activators to promote healthy brain aging and longevity, which has been voted on and funded.
Overview: This research project rapidly identifies new Alzheimer’s disease (AD) drug candidates using artificial intelligence (Fang-AI) and laboratory validation platforms (including C. elegans, mice, and iPSCs). Dr. Evandro Fang's research team is one of the first to propose the critical role of defective apoptosis in the onset and progression of AD and has demonstrated that inducing apoptosis in various AD animal models can inhibit memory loss. The team has established the Fang-AI laboratory validation platform and successfully screened two lead compounds as drug candidates for AD. The project plans to use WP1 to screen new apoptosis activators from the compound library of the Finnish Institute of Molecular Medicine (FIMM) using Fang-AI and the laboratory validation platform, and through WP2, to perform AI structural modifications and laboratory validation on two natural compounds, EFF-AA and EFF-BA. The total cost of the project is expected to be between $2.5 million and $4 million, and the DAO will own 100% of the project and related intellectual property.
Extended Understanding:
YL Comment: Both aging biology and Alzheimer’s disease are unsolved mysteries, and any effective results along the journey are valuable assets for the future.
VDP-32 Hyperspectral Imager for Early Diagnosis of Alzheimer’s Disease
VDP-32: Hyperspectral Imager for Early Diagnosis of Alzheimer’s Disease
https://snapshot.box/#/s:vote.vitadao.eth/proposal/0x8df2891d818420c366cf9c4c48ad576db87e0dc292c16fc9d8caa7be3d5fae52
Summary: This proposal aims to raise €30,000 to fund the development of transistor camera technology by Mantis Photonics, designed for early screening of Alzheimer’s disease by detecting retinal amyloid beta peptides.
Overview: Alzheimer’s disease is a leading cause of dementia worldwide, and there is currently no simple early diagnostic method. Mantis Photonics AB is developing a transistor camera for retinal imaging to enable early screening for Alzheimer’s disease. This camera can be installed on conventional retinal imaging devices and is expected to cost significantly less than existing products on the market, facilitating widespread adoption. The project has already obtained two patents and has a peer-reviewed proof-of-concept study supporting its effectiveness.
Extended Understanding:
YL Comment: Both aging biology and Alzheimer’s disease are unsolved mysteries, and any effective results along the journey are valuable assets for the future.
VDP-39 Funding Longevity Hacker Film
VDP-39 Funding Longevity Hacker Film
https://snapshot.box/#/s:vote.vitadao.eth/proposal/0x8df2891d818420c366cf9c4c48ad576db87e0dc292c16fc9d8caa7be3d5fae52
Summary: The VitaDAO community voted on proposal VDP-39 to invest $100,000 in Michal Siewierski's documentary "Longevity Hackers" to promote scientific research in the field of healthy longevity and raise public awareness and interest in this area.
Overview: The VDP-39 proposal requests up to $100,000 in funding for the documentary "Longevity Hackers," produced by director Michal Siewierski, aimed at promoting research in the field of healthy longevity and lifespan extension, while providing additional exposure to the industry to accelerate research on anti-aging drugs, therapies, and surgeries. The VitaDAO community and ideological working group have successfully raised awareness of healthy longevity and lifespan extension research through various means, including online articles, Clubhouse journal club meetings, Twitter Spaces, and YouTube content. However, this awareness has primarily been limited to those already interested in the aging field or the Web3 space. The project aims to expand the community's visibility and support community growth and educational themes through investment in the film and anticipated financial returns. "Longevity Hackers" follows Emmy-nominated director Michal Siewierski as he explores the latest research and scientific breakthroughs in the fields of aging and healthy longevity. The film is produced by New Roots Films, an independent film company based in Phoenix, Arizona, co-founded by Michal Siewierski and Ruben Figueres. Michal Siewierski is an internationally renowned documentary filmmaker and television producer, while Ruben Figueres is an entrepreneur and media expert with over two decades of experience in media, business, and advertising. The film is a $2 million project, including promotion, distribution, and high-quality production costs. So far, the project has secured funding from LongevityTech.fund and other investors, and filming has begun over the past six months, which will shorten the time to market for the film and the start of investor returns.
YL Comment: Film dissemination remains a mainstream adoption method for the public today; although time passes, films can be preserved for future generations to explore!
VDP-46 Repair Biotechnologies
VDP-46 Repair Biotechnologies
https://snapshot.box/#/s:vote.vitadao.eth/proposal/0x843c0e546ecfdcfb850ba00e88bcfd8c4a1e9204f838342dbbf98a81606a50f6
Summary: Repair Biotechnologies is a preclinical biotechnology company developing a universal cell therapy for treating atherosclerosis, aimed at reducing the risk of cardiovascular events and improving the efficacy of existing drug treatments.
Overview: The company focuses on developing a novel atherosclerosis therapy that modifies cells to safely break down excess cholesterol. This therapy, based on universal cells, may reduce the risk of cardiovascular events and improve the efficacy of existing drug treatments. The company's technology has shown encouraging results in cell lines and mouse models, and it is currently working to complete the development of the candidate therapy and seek approval for clinical trials. Repair Biotechnologies' treatment approach is based on enhanced macrophages that can break down cholesterol and is expected to be applicable to other cell types and disease indications. Since its inception, the company has raised over $2.7 million and is conducting a new round of financing to fund preclinical research and clinical trials. The proposal has undergone scientific and commercial evaluation by the Longevity-Dealflow working group and has received decentralized voting support from VITA token holders.
Extended Understanding:
YL: According to the World Health Organization, cardiovascular diseases are one of the leading causes of death globally. Therefore, the demand for effective treatment options for atherosclerosis and hypercholesterolemia will continue to grow.
VDP-85 HDAX Therapeutics
VDP-85 HDAX Therapeutics
https://snapshot.box/#/s:vote.vitadao.eth/proposal/0x3f1bf4f88a3e122a446d68c91dcb10a9db0267bb31cbbc11f09fcc46335eb72a
Summary: HDAX Therapeutics is a preclinical drug discovery company focused on developing novel small molecule drugs for treating neuropathology and inflammation, with its HDAC6 inhibitors showing higher blood-brain barrier penetration and lower toxicity.
Overview: HDAX Therapeutics is a preclinical drug discovery company based at the University of Toronto, focusing on developing treatments for pathologies caused by histone deacetylases (HDACs), such as neuropathy and inflammation. The company's primary research target is HDAC6, whose inhibition has shown potential to extend lifespan in animal models. HDAX has designed novel small molecule drugs with excellent selectivity and potential through its unique dual-coordination binding mechanism, capable of overcoming the shortcomings of traditional HDAC6 inhibitors, such as weak binding, non-specific toxicity, and poor pharmacokinetic properties. HDAX's lead drug candidate has demonstrated good blood-brain barrier penetration and safety in mouse models.
HDAX is composed of a team of experienced scientists and entrepreneurs with a strong background in drug discovery and entrepreneurship. The company was founded in the laboratory of Professor Patrick Gunning, a renowned chemist and serial entrepreneur. HDAX has won multiple startup competitions, raised over $340,000, and has applied for patents for its lead compounds.
Extended Understanding:
YL: In simple terms, this field addresses the painful symptoms experienced by cancer patients undergoing chemotherapy, as well as conditions like Alzheimer’s, Parkinson’s, and heart disease.
VDP-89 ExcepGen Inc - RNA Therapy for Longevity
VDP-89 ExcepGen Inc - RNA Therapy for Longevity
https://snapshot.box/#/s:vote.vitadao.eth/proposal/0x139c0b0736773e2b4b69123117e453c7f7ca947ff2584b30788340fb84c42de4
Summary: ExcepGen Inc is developing an RNA therapy platform called RNAx, aimed at enhancing the efficacy of RNA vaccines, particularly against hard-to-target antigens like the universal influenza virus, by optimizing RNA delivery and regulating cellular signals.
Overview: ExcepGen Inc aims to develop a new generation of vaccines and therapeutic drugs through its innovative RNAx platform by improving RNA delivery and cellular signal regulation. The RNAx technology can produce a regulatory protein that slows down signal transmission between the nucleus and cytoplasm, reducing stress and endogenous immune signals, thereby enhancing the expression efficiency of RNA payloads. The company is applying this technology to produce RNA vaccines targeting difficult-to-handle antigens, such as the influenza virus.
ExcepGen has demonstrated the effectiveness of the RNAx platform in experiments, significantly increasing RNA expression in mouse models and human BJ cells while reducing or eliminating the release of harmful inflammatory factors. The company is focusing on developing a universal whole-spore influenza vaccine and plans to expand its product line to include vaccines, protein replacements, and gene editing.
ExcepGen's team has a strong technical background, having been educated at the University of Oxford and founded the company to bring reliability to genetic drugs. The company is raising funds, including $100,000 allocated for the VitaDAO community to support laboratory research, scientific operations, and immunogenicity studies in animal laboratories.
Extended Understanding:
YL: This is a universal influenza vaccine, notable for its potential use not only in treating influenza infections but also in prevention scenarios, such as regulating immune responses.
VDP-112 Cyclarity - Novel Cyclodextrin Molecules for Various Aging-Related Diseases
VDP-112 Cyclarity - Novel Cyclodextrin Molecules for Various Aging-Related Diseases
https://snapshot.box/#/s:vote.vitadao.eth/proposal/0xeafce7c4610f9398048d7ed93d0bc5a083956224eec5f4e8f7ed5152f9f631d1
Summary: Cyclarity Therapeutics is a startup biotechnology company developing a novel cyclodextrin capsule drug based on computational design, aimed at extracting harmful biomolecules, particularly oxidized cholesterol, accumulated in the body, especially in cardiovascular diseases.
Overview: Cyclarity Therapeutics (CTx) is developing a cyclodextrin capsule drug that can extract harmful biomolecules accumulated during aging from cells and tissues. Their primary drug target is oxidized cholesterol, particularly 7-ketocholesterol (7KC), which is a significant factor in various age-related diseases such as cardiovascular diseases, cataracts, strokes, and cirrhosis. CTx is also developing a computational platform that combines artificial intelligence and machine learning to design novel cyclodextrin molecules targeting any objective. Their drug candidate UDP-003 effectively binds to 7KC, reversing foam cell formation in humans and restoring their phagocytic function. Pharmacodynamic studies of UDP-003 indicate it has a short half-life and high bioavailability. Currently, CTx is preparing for Phase I clinical trials and plans to conduct Phase II clinical trials to evaluate the overall effectiveness of its drug strategy. CTx has completed Good Manufacturing Practice (GMP) drug production and is conducting general toxicology studies under Good Laboratory Practice (GLP). They have completed a seed round of $3.95 million and are raising $3-4 million in bridge financing to prepare for and start Phase I clinical trials. The CTx team includes scientists and managers with extensive R&D experience.
Extended Understanding:
YL: "One pill cures all diseases." UDP-003 can be applied to various other diseases such as AMD, NAFLD, Alzheimer's disease, and COPD. AMD primarily affects vision, especially in the elderly. NAFLD is a disease associated with fatty liver, often related to metabolic syndrome. COPD is a chronic lung disease that primarily affects respiratory function and is usually associated with smoking.
VDP-120 Oisín Biotechnologies - Gene Therapy for Health and Longevity
VDP-120 Oisín Biotechnologies - Gene Therapy for Health and Longevity
https://snapshot.box/#/s:vote.vitadao.eth/proposal/0x6889bb02f936c73bf82d4f181e4cdd36efce5fabb7b49f47f80a6e0108d9c023
Summary: Oisín Biotechnologies is a company focused on developing gene medicine solutions to treat age-related diseases, with its technology platform Fusogenix Proteo-Lipid Vehicle (PLV) capable of effectively delivering specific DNA and RNA to treat age-related diseases such as muscle atrophy.
Overview: Oisín Biotechnologies is dedicated to developing gene medicine therapies to address aging and related diseases. Its primary goal is to enhance physical strength in the elderly by increasing muscle mass, thereby preventing and treating age-related diseases such as muscle atrophy. The company's technology platform, Fusogenix PLV, can safely and cost-effectively deliver specific genetic material and has shown potential in selectively eliminating fat cells and insights into cells in animal and human tissue experiments. Oisín's research results indicate that a single treatment can significantly increase muscle size and physical strength. Additionally, the company has conducted high-dose tolerance studies in non-human primates, and its PLV platform has been validated for safety in human Phase II clinical trials of COVID vaccines.
Oisín faces significant opportunities as the global aging population is expected to increase the prevalence of age-related diseases. The company's Follistatin gene therapy is believed to effectively treat muscle atrophy and has the potential to extend lifespan. Oisín holds extensive intellectual property, including exclusive rights to the Fusogenix PLV patent portfolio and multiple patents related to its specific goods and therapeutic applications. The company is seeking funding to advance its research and has reserved $50k in SAFE investment for the VitaDAO community to facilitate collaboration. Oisín's budget plan shows total expenditures of nearly $4.6 million in R&D, personnel salaries, consulting, laboratory leasing and insurance, legal, and intellectual property.
Oisín's team consists of seasoned leaders in the biotechnology industry, including CEO and founder Matthew Scholz, who has years of experience in founding and managing biotechnology companies, along with other executives and advisors with rich research and development experience.
Extended Understanding:
YL: The known methods for muscle gain are diet and exercise. Oisín stimulates muscle growth through biotechnology without relying on traditional exercise, which is particularly beneficial for individuals with disabilities and patients facing muscle loss during treatment for cancer, heart disease, and diabetes.
VDP-126 [Funding] Remedium Bio
VDP-126 [Funding] Remedium Bio
https://snapshot.box/#/s:vote.vitadao.eth/proposal/0xc4cb21033ebddc07a54ebc4226cfc8dffdda3eb800743bfbf64279d056f36add
Summary: Remedium Bio is a regenerative medicine biotechnology company that has developed the only adjustable-dose gene therapy platform technology, Prometheus™.
Overview: Remedium Bio focuses on age-related diseases and significant unmet clinical needs, with its leading product being a regenerative gene therapy for osteoarthritis that increases the expression of Fibroblast Growth Factor 18 (FGF18) through a single injection, promoting the formation and maintenance of healthy cartilage. The Prometheus™ platform overcomes the limitations of current gene therapy technologies by providing adjustable-dose treatment options that can replace multiple muscle injections with a single injection, significantly reducing treatment costs. Additionally, Remedium Bio is developing a single-injection therapy for treating obesity and type 2 diabetes, which has shown the same efficacy as daily injections of Exenatide in animal models while reducing drug-related side effects. The company is raising $15 million in Series A financing to bring three key assets to the clinical trial stage and has already advanced its technology into the clinical efficacy validation stage through preliminary fundraising. Remedium Bio has an experienced team and strong intellectual property protection, with its technology and products expected to have a significant impact in multiple areas, including arthritis, diabetes, obesity, and other anti-aging treatments.
Extended Understanding:
YL: Arthritis, diabetes, and obesity are prevalent diseases with a wide range of applications. Conclusion:
The above was initially organized in the Mirror draft box of DeSci.money on December 19, 2023, and is being reorganized and released today, hoping to assist you in your DeSci investment journey. DYOR!
免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。
